Reuters logo
BRIEF-Pfizer says U.S. FDA and EMA accept regulatory submissions for bosuliffor
August 29, 2017 / 11:16 AM / 24 days ago

BRIEF-Pfizer says U.S. FDA and EMA accept regulatory submissions for bosuliffor

Aug 29 (Reuters) - Pfizer Inc

* U.S. FDA and European Medicines Agency accept regulatory submissions for Bosulif® (bosutinib) for the treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia

* Says ‍prescription drug user fee act (PDUFA) goal date for a decision by FDA is in December 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below